Appropriate and effective management of rheumatoid arthritis

F C Breedveld, J R Kalden

Early referral (at <3 months) and early DMARD treatment enable the course of RA to be changed. Once the disease has become aggressive it is much harder to treat and improvements will not be as great as they would have been with earlier treatment. The latest strategies and treatments enable remission to be achieved in many more patients than formerly.

RA DISEASE MANAGEMENT: A SHIFTING PARADIGM

With the availability of new treatments for rheumatoid arthritis (RA) and increasing expectations for patient outcomes, the treatment paradigm for patients has changed dramatically over the past few years. As patients and their physicians are presented with more treatment options, it is increasingly important that rheumatologists continue to reach a consensus on the appropriate and effective management of RA and implement treatment guidelines to the full benefit of patients.

There are a greater number of, and better, RA management tools and processes than ever before. Rheumatologists know more about the pathogenesis, course, and progression of RA, and have improved ways of measuring disease activity. There are even more traditional and biological disease modifying antirheumatic drugs (DMARDs) in the treatment armamentarium and many more combinations in which to use them. There are indications that these therapeutic agents should be used in the early "window of opportunity" to help patients with RA achieve long term and sustained improvement. In addition, international and national guidelines are continually and intensively being refined to encourage early and more aggressive intervention in patients with RA. These tools and processes, in turn, permit rheumatologists to set higher goals for patients. The latest strategies and treatment options open the way to bring many patients with RA into low disease activity and remission.

ECONOMIC BURDEN OF RA

Despite the use of traditional treatments, RA still progresses linearly over time, leading to premature mortality, increased morbidity, significant decrease in quality of life (pain, fatigue, depression), and functional and work disability. Several patient outcome measures—the Health Assessment Questionnaire (HAQ), Disease Activity Score (DAS), and Short Form 36—are essential to quantifying and predicting the economic impact of the disease. Of these, the HAQ is very predictive of functional and work disability, cost of disease treatment, and joint replacement surgeries.

The economic burden of RA can be dichotomised into direct healthcare costs and indirect costs, including loss of productivity. Annual healthcare costs correlate well with degree of disability. For example, a North American study by Fries et al showed that the most severe disease expression of RA has the greatest costs. Patients with an HAQ score of 3 accounted for three times the expenditures of patients with an HAQ score of 1 (more than $45 000 per patient over five years is approximately $15 000). More than 50% of the money spent goes to hospital admissions. However, these hospital admission dollars are spent on only 10% of all patients with RA. Saving costs in hospital admissions would have a big impact on making more resources available for a significantly greater number of patients.

"Savings on high hospital costs, which benefit only a few patients, would allow more patients to be treated"

Indirect productivity costs are primarily related to employment (change of job, reduced work, loss of job, early retirement, and decreased income). In these areas, RA is much more of an economic burden than osteoarthritis. Treatment of RA has demonstrated an impact on long term outcomes and mortality. A 10 year prospective follow up of patients receiving methotrexate (MTX) showed that MTX non-responders have a 5.6-fold increase in mortality compared with the general population, and, in a study by Choi et al, patients with severe RA who were treated with MTX showed a 60% reduction in mortality. Increasingly successful treatments, such as biological agents, are expected to reduce mortality further.

Abbreviations: ACR, American College of Rheumatology; CTLA-4, cytotoxic T lymphocyte antigen-4; DAS, disease activity score; DMARDs, disease modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; IL, interleukin; MAF, matrix metalloproteinase; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
NEW INSIGHTS INTO RA PATHOGENESIS

The most characteristic feature of RA is synovial proliferation, which ultimately leads to joint destruction. Part of this process, cartilage destruction, is mediated by several extracellular factors, including matrix degrading enzymes such as lysosomal cathepsins, matrix metalloproteinases (MMPs), and membrane-type MMPs. Because it is uncertain which of these factors contributes most significantly to joint inflammation and destruction, and several have other important physiological functions, the development of agents that specifically inhibit these inflammatory elements simultaneously has, until now, not been successful.

The aetiology of RA can be succinctly but non-specifically characterised as the interaction of a genetically susceptible host with an unidentified, external inflammatory stimulus. Because the cause and initiating factors of RA are unknown, RA-specific treatments are not under investigation at this time. Current treatments target a variety of immune processes and are based on recent insights into RA pathophysiology, which are expanding and evolving with our rapidly increasing understanding of the relationships between cell biology and inflammation. Knowledge of the mechanisms driving tissue destruction in RA has led to the evaluation of several therapeutic principles and new biologic agents that target immune processes. Table 1 summarises these targets and therapeutic approaches.

“Cytotoxic T lymphocyte antigen-4 is a potential blocker of T cell activity”

A few of these target therapeutic agents are interesting and warrant further discussion. CD28 is a glycoprotein identified as providing non-antigen driven costimulatory signals to complement T cell receptor driven signals during T cell responses, leading to optimal T cell activation. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a homologue of CD28 expressed by activated T cells. A soluble fusion protein composed of a CTLA-4 molecule linked to the fixed chain or FC portion of human immunoglobulin antibody IgG1 is being expressed for its ability to block the interaction of CD80/CD86 with CD28, as a way of inhibiting T cell activation. CTLA-4 may not only inhibit activation of proinflammatory Th1 mediated autoimmune cells, such as are found in RA, but also prevent the differentiation of immunomodulatory Th2 effectors. Randomised, controlled trials of CTLA-4-Ig in RA are underway.

Although RA is predominantly a T cell mediated disease, B cell depletion therapy is another new approach that is proving viable. Rituximab, approved to treat the most common type of low grade non-Hodgkin’s lymphoma, is a humanised monoclonal antibody directed against CD20, a B cell restricted differentiation antigen. Recent findings indicate that B cell depletion in patients with RA has a selective effect on autoantibody concentrations. Relapse of RA is associated with rises in specific autoantibody concentrations, but not necessarily an increase in B cells.

Described in detail during the past 10 years, tumour necrosis factor (TNF) is a central cytokine in RA pathogenesis. It participates in the early stages of the inflammatory cascade promoting downstream mediators, ultimately leading to bone and joint destruction. TNF stimulates the synthesis of other proinflammatory cytokines, including interleukin (IL)1, IL6, IL8, and granulocyte macrophage colony stimulating factor; and induces endothelial cells to express adhesion molecules that attract leucocytes into affected joints. It also stimulates the production of MMPs by synovial macrophages, fibroblasts, osteoclasts, and chondrocytes; and suppresses the neosynthesis of cartilage proteoglycans. Produced mainly by monocytes and macrophages, TNF influences all aspects of the disease, and is a major contributor to the pathological and destructive changes that occur in patients with RA.

The inflammatory cytokine pathways can be inhibited through several therapeutic approaches. One is direct cytokine neutralisation. For TNF, this includes either monoclonal antibodies (adalimumab and infliximab, which are specific to TNF) or TNF soluble receptor fusion constructs (etanercept, which binds to both TNF and lymphotoxin). Using this approach, TNF antagonists directly bind to TNF before it can bind to its cell surface receptors. Another approach is receptor blockade, which has been used to inhibit IL1 through anakinra, a recombinant IL1 receptor antagonist, which directly blocks IL1 cell receptors. Another approach is indirect inhibition by blocking “upstream” cytokines that have a role in stimulating production of the cytokine of interest. There is evidence that inhibition of TNF and IL1, in effect, block paracrine and autocrine effects of these cytokines. This may be one of the mechanisms through which inhibition of other cytokines, such as IL6 (for example, with a monoclonal antibody against the IL6 receptor), mediates their effects. Another approach is the inhibition of TNF cleaving enzyme, an enzyme that cleaves TNF from the cell surface. Inhibition of TNF cleaving enzyme would prevent TNF from becoming a soluble cytokine. Although the last two approaches may hold future promise, the three anti-TNF agents—infliximab, a chimeric monoclonal antibody; etanercept, a soluble receptor construct; and adalimumab, a fully human monoclonal antibody—are currently available and have been shown to be safe and effective in the treatment of RA.

“Retroviral sequences may be responsible for the activation of synovial fibroblasts”

In addition to cytokine mediated mechanisms, a new pathway has been proposed to further explain the activation of synovial fibroblasts. Since recognising through mouse models that fibroblasts may become activated without the interactions of macrophages and T cells, researchers have been searching for alternative fibroblast activators. They suggested that retroviral sequences might be responsible for this phenomenon.

Table 1 Biological interventions investigated in rheumatoid arthritis

| Cell surface-directed therapy | Anti-CD3 mAb, anti-CD4 mAb, anti-CD5 mAb, anti-CD7 mAb, anti-CD20 mAb (rituximab), anti-CD25 mAb, anti-CD28 mAb, anti-CD52 mAb, IL2 fusion protein, anti-ICAM-1, CTLA-4-Ig (CD86 binding) |
| Cytokine targeted therapy | TNF antagonist (mAb, soluble TNF receptor) | IL1 receptor antagonist |
| | IL6 antagonist (mAb against IL6 or IL6 receptor) | Administration of cytokines (IL4, IL10, IFNc, and IFNc) |
| Tolerance induction | Application of antigens (collagen II, HCGP-39) | T cell or T cell receptor vaccination |
| | Interference with T cell activation (CTLA-4-Ig) | Inhibition of chemokines |
| | Inhibition of complement activation | High dose intravenous immunoglobulins |
| | Plasmapheresis, immunoabsorption column | Autologous bone marrow transplantation |

mAb, monoclonal antibody; IL, interleukin; ICAM, intracellular adhesion molecule; CTLA-4, cytotoxic T lymphocyte antigen-4; Ig, immunoglobulin; TNF, tumour necrosis factor; IFN, interferon. Adapted with permission from Breedveld FC.
The human retrotansposon or L1—expressed at the site of invasion with the synovial cells invading cartilage—proved to be a viable explanation. Because L1 was found at the site of invasion, scientists further investigated if it would independently engage the p38 intracellular signalling pathway in parallel with the well known p38 kinase activation, which is driven by the cytokine-to-cytokine receptor interactions of TNF, IL1, and other cytokines. Work by Gay et al verified the presence of p38, a cytokine independent pathway that also results in the production of matrix degrading enzymes such as MMP. Possibly, these two pathways complement each other, and one or the other may be more prevalent in different patients. Such a circumstance would plausibly explain the varying degrees to which different patients respond to biological agents.

**IMPORTANCE OF EARLY AND AGGRESSIVE RA TREATMENT**

Historically, DMARDs have been used cautiously in patients with RA to avoid toxicities linked to high dosing or combination therapy. However, several randomised, controlled trials demonstrate that an early and aggressive approach to treatment is essential for controlling disease activity effectively and achieving optimal results. Early and aggressive therapy means using the best treatments available, and using them early to prevent irreversible disease progression. Early and aggressive treatment includes one or more DMARDs at effective doses—doses reached early in the treatment process. In addition, aggressive treatment requires stringent patient monitoring to achieve maximum therapeutic efficacy with minimum toxicity.

Defining “early” is an important matter. By survey, more than two thirds of European rheumatologists consider disease duration of 3 months or less as “early RA.” However, these same surveyed rheumatologists said that 50% of their patients are referred after 6 months of disease. Many patients are not seen until up to 1 year or more, and data from Emery et al indicate that 60% of patients have erosive disease by 1 year. Other data suggest that approximately 75% of patients have joint erosions by the 2 year mark, and 25% have erosions as early as 3 months. In contrast, a study by Machold et al on time to initiation of traditional DMARDs indicates that by 3–4.5 months from the onset of symptoms 70% of Austrian patients are receiving DMARDs. Over the course of 1 year, joint erosions had increased from 10% to 25% of patients, despite DMARD treatment started within the first 3–4.5 months.

“Early aggressive treatment with DMARDs is needed to achieve the greatest effect on long term outcome”

Lard et al compared patients whose treatment started within 15 days of referral with patients treated after a delay of about 4 months. After 2 years, median total Sharp scores for the delayed group were approximately four times higher than for the early treatment group. Moreover, in patients in the early treatment group, radiographic damage stopped progressing. Nell et al compared the DAS28 scores over time of patients with very early RA (<3 months) with those with late-early RA (6 months–3 years). Patients in both groups had baseline DAS28 scores in the high disease activity range. Although both groups had statistically significant improvements over time, the late-early group reached a plateau in the moderate activity range and the very early group improved into the low activity range. The largest difference in relative improvements occurred during the first year. During years 2 and 3, the improvement trend lines ran in parallel. The study by Lard et al and another by Emery et al show that giving early treatment with traditional DMARDs improves long term outcomes and quality of life more than delaying treatment by as little as 3 months.

In support of early and aggressive treatment, Emery and colleagues developed an early referral algorithm for newly diagnosed RA. Patients should be referred to rheumatologists upon the mere clinical suspicion of RA, which is supported by the presence of any of the following: three or more swollen joints; metatarsophalangeal/metacarpophalangeal involvement by squeeze test; and morning stiffness of 30 minutes or more.

Clinical evidence showing that early treatment is more beneficial than later treatment is further supported by data on the immediate and sustained reduction of C reactive protein and erythrocyte sedimentation rate values during DMARD treatment. These reductions indicate that the first DMARD used appears to be more effective than subsequent DMARDs, regardless of the type of initial DMARD used. This is also reflected in retention rates for the first DMARD used compared with subsequent DMARDs, which shows that patients continue to receive the first DMARDs for almost twice as long as their fourth and subsequent DMARDs.

Evidence also indicates that aggressive treatment can be better than more conservative treatment. Data on MTX use show that approximately 60% of patients receiving high dose MTX (>12.5 mg/week) are still taking the drug after 6 years, whereas fewer than 37% receiving low doses are still taking the drug after the same time period. One very interesting trial is the Combinatietherapie Bij Reumaatode Arthritis (COBRA) trial in early RA, which compared sulfasalazine monotherapy with sulfasalazine combination therapy with prednisolone and MTX in a step-down approach. During this trial, prednisolone and MTX were sequentially discontinued over time. After 56 weeks of treatment, results for a pooled index of outcomes were better in the patients who underwent the step-down approach. The results of this trial indicate that this aggressive approach in patients with early RA improves patients’ outcomes.

Trial data show that patients who receive biological agents early in RA achieve greater decreases in the signs and symptoms of the disease than patients taking MTX. At 52 weeks in a trial of patients with early RA taking etanercept v placebo, 72% of patients taking 25 mg achieved American College of Rheumatology (ACR)20 v 65% for MTX alone, 49% achieved ACR50 v 43% for MTX alone, and 25% achieved ACR70 v 22% for MTX alone. Other trial data show that patients have significantly greater inhibition of radiographic progression when the biological agents are started earlier in the disease process.

Data on early and aggressive treatment suggest there is a “window of opportunity” very early in the disease process—<3 months of disease duration. Early referral and early DMARD treatment provide a unique opportunity to change the course of RA. The somewhat small but important window may exist between the start of symptoms and the start of radiographic damage. This means that once the disease has become aggressive, it is much harder to treat, and improvements will probably never be as great as they would have been with earlier treatment. The challenges rheumatologists face are to get patients referred, diagnosed, and receiving DMARD treatment rapidly (fig 1).

**TRADITIONAL DMARDs AND THE ROLE OF BIOLOGICAL AGENTS**

With traditional DMARDs, rheumatologists and other treating physicians use two main treatment approaches—monotherapy and combination therapy. Monotherapy is a first line treatment approach and usually involves sequential
monotherapy. Thus, treatment of patients is started with one DMARD, and, if this is not efficacious or is toxic, that DMARD is discontinued and another started; the process is repeated as necessary. Sulfasalazine, hydroxychloroquine, and MTX are the most commonly used traditional DMARDs, and MTX, in particular, has been used most effectively in these patients. Corticosteroids have been an important but controversial RA treatment. They have dramatic, short-term anti-inflammatory properties, but at high doses, or given over a long period, may have devastating side effects. Corticosteroids can be effective in helping patients to manage pain and functional disability. In studies of patients with early, active RA, they have helped, in combination with other treatments, to substantially reduce the rate of radiologically detected disease progression. However, most studies, and 50 years of use, show that corticosteroids are inadequate as sole treatment for RA.

Combination therapy can be used in the following different ways: (a) a continuous approach, in which the rheumatologist prescribes two or more DMARDs with the intention of continuing all the DMARDs involved; (b) a step-up approach, in which the rheumatologist begins with the conventional monotherapy approach and adds subsequent DMARDs if adequate efficacy is not achieved; and (c) a step-down approach, the most aggressive of the three, in which the rheumatologist initiates several DMARDs at the onset, with the intention of discontinuing the most toxic or the most expensive, once goals are achieved. Research results are controversial. However, much of the data suggest that combination therapy is more efficacious than monotherapy, and not necessarily more toxic.

When efficacy is examined, traditional DMARDs are found to have several benefits. They improve the signs and symptoms of RA, reduce inflammation, improve functional/disability status in comparison with non-steroidal anti-inflammatory drugs (NSAIDs) in early RA, slow down radiographic progression, provide dosing flexibility, and have well studied and quantified toxicity and drug interaction profiles. However, they also have several important limitations. They have a delayed onset of action (1–6 months in most cases); some have less proved effectiveness on radiographic disease progression and health-related quality of life; require close monitoring because of multiple toxicities; provide for difficult and complex dosing regimens; provide limited long-term sustainability; and seldom yield treatment-free remissions. Thus, 50% of patients taking MTX discontinue because of inefficacy or toxicity after 5 years.

Arthroplasties, including total joint replacements, have been reported in 17–25% of patients with RA, of whom, 75% had received DMARD treatment.

The biological DMARDs have arisen out of the need to deal with these limitations. Over the past 70+ years, RA management has evolved from very cautious, very modestly effective treatment, based on a reactive approach and almost solely on symptom relief, to a proactive, early, and aggressive treatment approach, designed to be comprehensive and prevent the devastating effects of the disease. In the 1930s and 40s, gold, penicillamine, and hydroxychloroquine dominated, followed by steroids in the 50s and NSAIDs in the 60s, with limited success. Sulfasalazine made its debut in the 60s, MTX in the 80s, and combination therapy with traditional DMARDs in the early 90s. Most of these treatments had limited and unpredictable efficacy, relying heavily on affecting the outward manifestations of inflammation rather than underlying disease activity.

Without many of the limitations associated with traditional DMARDs, the first biological agents were approved for the treatment of patients with RA in 1998 and provided a new therapeutic standard. TNF antagonists, in particular, provide a predictable response for both efficacy and safety, either in combination with MTX, in combination with standard care, or as monotherapy. For example, data reported by Weinblatt et al established the ability of etanercept with MTX to reduce the signs and symptoms of RA. The percentages of patients at 25 mg etanercept twice weekly to achieve ACR responses at 6 months were 71% for ACR20, 39% for ACR50, and 15% for ACR70. In the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy or ATTRACT trial, the percentages of patients at 3 and 10 mg/kg infliximab every 8 weeks plus MTX who achieved ACR responses at 54 weeks were 42% and 59% for ACR20, 21% and 39% for ACR50, and 10% and 25% for ACR70, respectively. In the Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis (ARMADA) trial, the percentages of patients at 40 mg adalimumab every other week in combination with MTX to achieve ACR responses at 6 months were 67% for ACR20, 55% for ACR50, and 27% for ACR70. Therefore, in combination trials with MTX, TNF antagonists generally showed a similar response pattern, a pattern informally referred to as the “60–40–20” rule, with about 60% of patients reaching ACR20, 40% reaching ACR50, and 20% reaching ACR70. Results obtained with anakinra in combination with MTX are lower, perhaps a result of the difficulty of blocking the IL1 pathway with a receptor antagonist as well as anakinra’s relatively short half life of 4–6 hours.

The limitations of traditional DMARDs such as MTX and leflunomide include toxicities, especially hepatotoxicities. For patients eligible for treatment with TNF antagonists, these effects can be overcome by using the TNF antagonists as monotherapy. This approach avoids compounding toxicities through combination therapy and gives patients intolerant to MTX or other traditional DMARDs more options. The two monotherapy trials for etanercept in early and established RA yielded a significantly higher response than placebo. In addition, despite patients’ very significant disease severity at onset and non-response to previous MTX treatment, ACR response rates in a monotherapy trial for adalimumab were statistically significantly higher than for placebo.

The TNF antagonists each share a rapid onset of action—often as early as 1 or 2 weeks. Infliximab demonstrated that more than half of ultimate responders attaining ACR20 did so by their first evaluations at week 2, and more than 90% at the 6 week evaluation. The ARMADA trial demonstrated that...
25% of patients receiving 40 mg adalimumab every other week achieved an ACR20 response in the first week of treatment, and about 75% of the patients who would respond did so by 4 weeks. Comparably, patients who responded to monotherapy in the adalimumab monotherapy study also did so by 4 weeks. Similarly quick responses have been seen for etanercept.

Several long term studies support the sustained response of TNF antagonists past 5 years. An open label extension study of etanercept demonstrated response durability at 5 years. At that time, mean tender joint count was less than 5. Sustained response to 4 years was also demonstrated by a long term rollover study of adalimumab with MTX in patients with partial response to MTX. In this study, one year ACR20 scores were sustained to 4 years, and ACR50 and ACR70 scores continued to rise. Likewise, one year DAS28 improvements were sustained to 4 years. Similar long term results have been seen for infliximab. Technical issues about the judgment of the results of open label extension studies were recently discussed.

With respect to health related quality of life, the ATTRACT trial showed a highly significant median improvement from baseline to week 54 in HAQ scores (0.1 for the patients taking placebo and MTX v 0.4 for patients taking infliximab and MTX, p<0.001) (with a change of 0.22 or more being clinically important). In addition, trials for etanercept and adalimumab showed that patients with partial response to MTX receive a clear clinical benefit from adding a TNF antagonist to their regimens. Moreover, improvement in physical function and health related quality of life were demonstrated through improvements well above the minimum clinically important differences in HAQ scores; and Short Form-36 physical component summary, pain, and vitality scores across several of the pivotal trials for infliximab, etanercept, and adalimumab.

TNF antagonists routinely inhibit radiographic progression. Infliximab and adalimumab, for example, yielded significantly smaller mean changes from baseline in total Sharp scores v placebo after 1 year in patients with significant disease (1.3 for infliximab 3 mg/kg every 8 weeks v placebo, p<0.001; and 0.1 for adalimumab 40 mg every other week v 2.7 for placebo, p<0.001). In addition, mean changes from baseline for joint erosions and joint space narrowing v placebo were also significantly smaller (joint erosions: 0.2 for infliximab 3 mg/kg every 8 weeks v 4 for placebo, p<0.001; and 0 for adalimumab 40 mg every other week v 1.7 for placebo, p<0.001; joint space narrowing: 1.1 for infliximab 3 mg/kg every 8 weeks v 2.9 for placebo, p<0.001; and 0.1 for adalimumab 40 mg every other week v 1.1 for placebo, p<0.001). In the Early Rheumatoid Arthritis trial of etanercept, the mean change in total Sharp scores after 2 years was 1.3 for the 25 mg group v 3.2 for placebo, p = 0.001; and 0.7 for the 25 mg group v 1.9 for placebo for joint erosions, p = 0.001. At week 52 the progression of erosion scores was respectively 0.47 and 1.03 (p = 0.002).

TNF antagonists are generally safe and well tolerated. Rare but important events have been reported for each. These include serious and opportunistic infections, including tuberculosis; malignancies; demyelinating disorders; administration reactions; congestive heart failure; autoantibody formation; and lupus-like syndrome. Although they have some safety considerations, TNF antagonists overcome several of the limitations of traditional DMARDs. They have a rapid onset of action, provide consistent responses, improve quality of life, significantly inhibit radiographic progression, provide sustained efficacy, and are well tolerated. Their benefit/risk ratio makes them a useful addition to the therapeutic armamentarium of the rheumatologist.

**RA TREATMENT GUIDELINES AND THE GOAL OF CLINICAL PRACTICE TODAY: REMISSION**

National guidelines and international and European consensus statements are important for several reasons. They standardise management and therapeutic approaches, consider all available evidence of positive and negative drug effects, summarise documentation of efficacy and toxicity, and consider cost effectiveness ratios. The international consensus statement, revised in May 2002, states that “TNF antagonists are recommended for the treatment of active RA after an adequate trial of another effective DMARD, of which methotrexate (MTX) is a commonly used example.” They may be added to pre-existing treatment or replace previous DMARDs or other biological agents. They are effective in MTX-naïve patients, and may be considered first line when other DMARDs are contraindicated. They should lead to significant, documented improvement within 12 weeks, or be discontinued, and should not be started or should be discontinued under certain conditions.

Criteria to consider when selecting which biological agent to use may include: target selection—TNF antagonist v IL1 antagonist; binding affinity; half life; patient preferences for administration; and formulation (ready to use liquid preparation v lyophilised formulation, necessitating reconstitution).

Today, a significant proportion of patients with mild, moderate, or severe RA receive NSAIDs and steroids before starting aggressive DMARD treatment. Many patients with moderate or severe disease receive suboptimal doses of traditional DMARDs as monotherapy or combination therapy. Biological agents are primarily being used only in patients with severe disease. However, the guidelines recommend that all patients with mild to moderate disease be treated with traditional DMARDs, and those with moderate disease should also be considered for biological therapy.

Historical RA management entailed controlling inflammation through conservative treatment with NSAIDS. DMARDs were withheld until there was clear evidence of joint damage and were added individually in slow succession as disease progressed. This approach yielded few long term remissions, and unsatisfactory outcomes. Current RA management, still evolving, includes early, aggressive treatment—with the goals of minimising long term joint damage and achieving remission. DMARD combinations including biological agents are used to a much greater degree.

Well defined guidelines, treatment and referral algorithms, and research on the safety and efficacy of traditional DMARDs and biological agents abound. Yet, the use of traditional DMARDs is still suboptimal. After decades of research, rheumatologists have better tools to diagnose and treat RA and measure disease activity, including a greater number of traditional DMARDs; biological agents, a new therapeutic standard; and increasingly sensitive laboratory markers, radiographic measurement tools, and patient-outcome measures. Rheumatologists also have better processes available through which to approach treatment. They have accumulated considerable evidence on early and aggressive treatment and guidelines that reflect this evidence to help direct therapeutic courses of action. With these new and better tools and processes, they can set a very high but realistic goal for their patients—remission (fig 2).

**ACKNOWLEDGEMENTS**

The concepts of RA management reviewed in this paper were discussed during an international scientific forum supported by an unrestricted educational grant from Abbott Laboratories.

We gratefully thank the following members for their contributions: Dr Christian Antoni, University Erlangen-Nürnberg, Germany,
Epidemiology, clinical course, and burden of disease; Professor Maxime Dougados, MD, René Descartes University, Cochin Hospital, Paris, France, “Traditional therapies”; Professor Paul Emery, MD, University of Leeds, United Kingdom, “Efficacy profile of adalimumab”; Professor Steffen Gay, MD, University Hospital, Zurich, Switzerland, “Pathophysiology”; Professor Edward Keystone, MD, University of Toronto, Mount Sinai Hospital, Toronto, Canada, “Anti-TNF biology: new therapeutic standard”; Professor Josef Smolen, MD, University of Vienna, Lainz Hospital, Vienna, Austria, “Early, aggressive RA therapy”; and Professor Leo van de Putte, MD, University Hospital, Nijmegen, The Netherlands, “Overview of TNF antagonists.”

References
